Core Insights - Defence Therapeutics Inc. is advancing its proprietary Accum® technology to enhance antibody-drug conjugates (ADCs) for cancer treatment, aiming to overcome current limitations in ADC efficacy and toxicity [1][5]. Company Developments - The company has successfully engaged with ADC companies at industry conferences, positioning itself as a supplier of its Accum® platform to improve drug delivery precision and reduce toxicity in cancer therapies [2][5]. - Defence has conducted studies demonstrating that its Accum® technology can significantly enhance the potency of ADCs, with a recent study showing a ~20-fold increase in anti-tumor efficacy in mouse models when comparing Accum®-Kadcyla to Kadcyla® alone [4]. Technology and Innovation - The Accum® technology allows for the precise delivery of ADCs in their intact form to target cells, which is expected to lead to increased efficacy and potency against cancer [6]. - The company aims to transform ADC cancer therapies by applying its Accum® technology across various antibodies and indications, establishing itself as a leader in ADC drug delivery [5].

Core Insights - The novel spliceosome targeting payload, PH1, shows potential in inducing cancer cell cytotoxicity and activating anti-tumor immunity through various mechanisms [1][3] - The combination of Trastuzumab-PH1 ADC with anti-PD1 therapy significantly outperforms Kadcyla® with anti-PD1 in achieving complete tumor regressions (74% vs. 42%, p<0.05) [1][12] - Akari Therapeutics is advancing its lead ADC candidate, AKTX-101, which targets the Trop2 receptor and utilizes the PH1 payload, aiming to enter clinical trials soon [7][9] Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs) [9] - The company’s innovative ADC platform allows for the generation and optimization of ADC candidates tailored to specific targets [9] - The PH1 payload is designed to disrupt RNA splicing in cancer cells, leading to cancer cell death and immune activation [9] Mechanism of Action - Trastuzumab-PH1 induces RNA mis-splicing, resulting in increased neoantigen generation and a subsequent rise in anti-cancer immune cells within the tumor microenvironment [4][12] - The combination therapy enhances immune responses, including the polarization of macrophages, increase in neutrophils, and expansion of B cell clones producing IgM antibodies [3][12] - The synergy between Trastuzumab PH1 and anti-PD1 therapy is attributed to their complementary effects on the immune system, particularly the expansion of gamma-delta T cell clones [3][12] Market Potential - The immuno-oncology therapeutic class is currently valued at approximately $50 billion per year, with the potential for significant growth through innovative therapies like those developed by Akari [1][4] - The unique results from the Trastuzumab-PH1 and anti-PD1 combination therapy could establish a new standard of care in cancer treatment, improving patient outcomes [6][12] Upcoming Events - Akari Therapeutics will host a live webcast on November 18, 2025, to discuss the presented data, providing insights for investors and analysts [1][8]